Evidence map›Paper›PMID 3427267›Full record

ArticleBritish journal of pharmacology1987

Spironolactone inhibition of contraction and calcium channels in rat portal vein.

C Dacquet, G Loirand, C Mironneau, J Mironneau, P Pacaud

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

C DacquetInstitut de Biochimie et Neurochimie du C.N.R.S., Université de Bordeaux II, France.
G Loirand
C Mironneau
J Mironneau
P Pacaud
Université de Bordeaux · FRInstitut de Biochimie et Génétique Cellulaires · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1. The effects of spironolactone have been studied on the mechanical activity of rat portal vein strips and the calcium channel currents of isolated cells using the patch clamp technique (whole-cell configuration). 2. Spironolactone (50 nM to 0.1 mM) depressed both K+-induced and twitch contractions within 5-6 min. This inhibitory effect was overcome by elevating the calcium concentration in the perfusing solution. 3. Spironolactone (60 microM) depressed the transient contractions induced in a Ca2+-free, EGTA-containing solution by either acetylcholine (0.1 mM) or noradrenaline (10 microM). The effect of spironolactone was dependent on a reduction in the filling of the internal calcium store. 4. Rapidly inactivating calcium channel current was maintained in the presence of spironolactone (60 microM), while slowly inactivating calcium channel current was blocked in a concentration-dependent manner. Half-inhibition of slow calcium channel current was obtained at concentrations between 5-7 microM. 5. Administration of spironolactone (10 microM) at rest reduced calcium channel current by about 70% (tonic inhibition). Repetitive depolarizations (300 ms long pulses to zero mV, applied between 0.05 and 0.5 Hz) had no further inhibitory effect on the inward current (absence of use-dependence). 6. When cells were held at depolarized membrane potentials at which slow calcium current was inactivated by about 80%, the inhibitory effect of spironolactone (10 microM) was similar to that obtained with cells normally polarized. Spironolactone (10 microM) had no effect on the voltage-dependence of inactivation of the calcium channel current. 7. Our results suggest that spironolactone acts primarily on the plasma membrane by depressing inward current through slow calcium channels. This effect may be explained by a preferential binding of the drug to the resting state of the slow calcium channel. In addition, spironolactone may depress contractions dependent on the release of calcium from the sarcoplasmic reticulum.

Indexed as

Calcium Channel BlockersAnimalsCalciumIn Vitro TechniquesMembrane PotentialsMuscle ContractionMuscle, Smooth, VascularPortal VeinRatsSpironolactoneCalciumCalcium Channel BlockersSpironolactone

Identifiers

PMID3427267
PMCPMC1853690
OpenAlexW2047865739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.